GARR Powers National Research and Education Network in Italy with Infinera Cloud Xpress 2
SUNNYVALE, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Infinera, provider of Intelligent Transport Networks, announced that GARR, Italy's national research and education network, deployed the Cloud Xpress 2, featuring the Infinite Capacity Engine (ICE4), to meet growing bandwidth demands driven by scientific computing applications. GARR's network reaches approximately four million users and connects over 1,000 public institutions across Italy with other international networks worldwide. GARR deployed the Cloud Xpress 2 to increase capacity and enable dynamic resource sharing between supercomputing centers operated by the National Institute for Nuclear Physics and CINECA, Italy's largest supercomputing consortium.
GARR selected the Infinera Cloud Xpress 2 for its unmatched combination of simplicity and capacity in a compact, easy-to-install optical networking platform. The Cloud Xpress 2 supports simple point-and-click provisioning and the highest plug-and-play combination of capacity and reach available. With the Cloud Xpress 2, GARR delivers 1.2 terabits per second of capacity with low latency between supercomputing centers. Infinera Instant Bandwidth enables GARR to activate additional capacity in minutes, reducing the initial cost of deployment while remaining responsive to bandwidth demands.
"GARR's high-performance network infrastructure delivers critical services for the Italian academic and scientific community," said Massimo Carboni, CTO. "It is imperative that our network delivers high capacity and low latency for important supercomputing and research projects using dedicated ultra-fast fiber links. The Infinera Cloud Xpress 2 meets these needs and enables GARR to accelerate service innovation to support the development of these critical projects."
"Research and education networks deliver substantial amounts of data in real-time transmission and rely on networks with high capacity, scalability and low latency," said Nick Walden, Infinera Senior Vice President, EMEA. "We are delighted to work with GARR to meet the increasing needs of the academic community and are committed to providing GARR with solutions that satisfy bandwidth demands with efficiency and low latency."
Tel. +1 (916) 595-8157
Tel: + 1 (408) 213-7150
Infinera (NASDAQ:INFN) provides Intelligent Transport Networks, enabling carriers, cloud operators, governments and enterprises to scale network bandwidth, accelerate service innovation and automate optical network operations. Infinera's end-to-end packet-optical portfolio is designed for long-haul, subsea, data center interconnect and metro applications. To learn more about Infinera visit www.infinera.com, follow us on Twitter @Infinera and read our latest blog posts at blog.infinera.com.
Infinera and the Infinera logo are registered trademarks of Infinera Corporation.
This press release contains forward-looking statements including, but not limited to the operational and technical advantages of deploying the Cloud Xpress 2 product. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Actual results may vary materially from these expectations as a result of various risks and uncertainties. Information about these risks and uncertainties, and other risks and uncertainties that affect Infinera's business, is contained in the risk factors section and other sections of Infinera's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 as filed with the SEC on May 10, 2018, as well subsequent reports filed with or furnished to the SEC. These reports are available on Infinera's website at www.infinera.com and the SEC's website at www.sec.gov. Infinera assumes no obligation to, and does not currently intend to, update any such forward-looking statements.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Infinera Corporation via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
USD TENDER OPERATION ANNOUNCEMENT26.5.2020 15:00:00 CEST | Press release
USD TENDER OPERATION ANNOUNCEMENT MAY-28-2020 Transaction type: Reverse TransactionOperation type:Liquidity providingTender date:MAY-28-2020Time for submission of bids14.00-14.30 (CEST)Start date:JUN-1-2020Maturity date:AUG-24-2020Duration:84 daysOffered volume:10.0 bln Min bid amount: 100 mlnMaximum bid amount: 4.0 blnMax number of bids:10Lowest interest supplement:0.25 percentage pointsMin bid rate:t.b.a.Allocation time:15.00 (CEST) on Tender date Approved counterparties are invited to submit bids to the Riksbank, tel +46 8 6966970 by 14.30 (CEST) pm on May 28, 2020. Confirmation of bids to e-mail: https://www.globenewswire.com/Tracker?data=m3O1JLVEmyGluQh0AvJvGpAt6AU1L2Qmmo7-ktvXU5fV3d13DU2X3whKS1qawLrAoNyGIVGKywGQ1AWND3wnpA== firstname.lastname@example.org
Corline Biomedical AB presenterar på Redeyes Growth Day 202026.5.2020 13:54:48 CEST | Pressemelding
Den 2 juni kl 14.00 presenterar Henrik Nittmar, VD i Corline Biomedical AB den senaste utvecklingen i bolaget på Redeye. Presentationen livesänds och kan följas på https://www.redeye.se/live/growth-day-2020 där presentationen även i efterhand kommer finnas tillgänglig, samt på vår bolagssida i Redeye Universe https://www.redeye.se/company/corline-biomedical. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: email@example.com Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: firstname.lastname@example.org Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administrati
Corline Biomedical AB presenterar på Redeyes Temaevent Orphan Drugs26.5.2020 13:49:07 CEST | Pressemelding
Corline Biomedical AB (”Corline”) kommer att presentera sin verksamhet på Redeyes temaevent Orphan Drugs. Presentationen sker kl 11:30 den 27 maj 2020 i Stockholm och livesänds via Redeyes hemsida. Konferensprogrammet och livesändningen görs tillgängliga via Redeyes hemsida https://www.redeye.se/live/orphan-27-maj. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: email@example.com Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: firstname.lastname@example.org Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans och sedan tidigare
Lundin Gold Inc. Announces C$50 Million Bought Deal Financing26.5.2020 13:30:02 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATES VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) -- Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) has announced today that it has entered into an agreement with BMO Capital Markets (“BMO”), under which BMO has agreed to buy on a bought deal basis 4,150,000 common shares (the “Common Shares”), at a price of C$12.05 per Common Share for gross proceeds of approximately C$50 million (the “Offering”). The Company has granted BMO an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The offering is expected to close on or about June 11, 2020 and is subject to Lundin Gold receiving all necessary regulatory approvals. Newcrest Mining Limited, which currently holds approximately 32% of the Company’s issued and outsta
PCI Biotech: Disclosure of voting rights for Chairman of the Board26.5.2020 13:20:03 CEST | Press release
Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 27 May 2020. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,171,710 additional shares. In total, Mr. Bøhn will represent and vote for 19.6 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 27 May 2020. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO, email@example.com, Mobile: +47 9400 5757
Prosafe SE: First quarter 2020 report – Adapting to a new reality26.5.2020 11:44:38 CEST | Press release
(Figures in brackets refer to the corresponding period of 2019) After several years of low activity across the industry, the company has presented a business plan and a restructuring proposal to lenders which – if approved as proposed – will result in a sustainable balance sheet. The revised business plan reflects a new reality in light of Covid-19, structural changes, oil price collapse, oversupply and anticipated impact on future activity and performance. Consequently, an impairment of USD 810.5 million was made to the book value of vessels in the quarter resulting in a negative book equity of USD 858.9 million by the end of the quarter. The company has sufficient liquidity of USD 184 million at the end of the quarter and continues to operate on a going concern basis on the assumption that there is justified hope to agree a sustainable financial solution with lenders. Recent highlights Prosafe implemented Covid-19 plans early to safeguard people and assets, and this has proven succes